ValuEngine upgraded shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) from a hold rating to a buy rating in a report released on Saturday morning.
HKMPF has been the subject of several other research reports. Zacks Investment Research cut Hikma Pharmaceuticals from a hold rating to a sell rating in a report on Friday, November 10th. Jefferies Group cut Hikma Pharmaceuticals from a hold rating to an underperform rating in a report on Wednesday, January 10th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. Hikma Pharmaceuticals presently has a consensus rating of Hold.
Hikma Pharmaceuticals (HKMPF) opened at $14.06 on Friday. Hikma Pharmaceuticals has a fifty-two week low of $12.40 and a fifty-two week high of $27.50.
TRADEMARK VIOLATION NOTICE: “Hikma Pharmaceuticals (HKMPF) Rating Increased to Buy at ValuEngine” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/01/17/hikma-pharmaceuticals-hkmpf-rating-increased-to-buy-at-valuengine.html.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.